Osage University Partners β 2026 Investments
6 investments dated 2026 Β· listed companies and verified rows first Β· show all
AssetWatch provides cloud-based asset monitoring software and sensor technology to help manufacturing and industrial facilities prevent unplanned equipment downtime.
Advanced ManufacturingEnterprise SoftwareIoTSaaSWesterville, US
William Zell(Executive Officer, Director)William Ruff(Executive Officer)Robert Lee(Director)Tad Dritz(VP of Development)Jeff Haskett(COO)Brian Graham(Executive Officer, Director)in
Co-investorsCerity Partners VenturesG2 Venture PartnersHarmonic Growth PartnersJobsOhio VenturesMonte Carlo CapitalOUP (Osage University Partners)+3 more
DualEntry is an AI-native enterprise resource planning (ERP) platform designed to replace legacy accounting systems for mid-market to enterprise businesses.
AI & Machine LearningEnterprise SoftwareFintechSaaSNew York, US
Santiago Nestares(Co-founder & CEO)inBenedict Dohmen(Co-founder)in
Co-investorsContraryKhosla VenturesLightspeed Venture PartnersGV (Google Ventures)Carya Venture PartnersLudlow Ventures+9 more
Precede Biosciences develops a blood-based diagnostic platform that profiles gene expression from cell-free DNA to reveal disease biology at the transcriptional level for drug developers and clinical trials.
AI & Machine LearningBiotechDigital HealthBoston, US
Rehan Verjee(Co-Founder, Chief Executive Officer, Board Director)Sylvan Baca(Co-Founder; Assistant Professor of Medicine, Dana-Farber Cancer Institute)Toni Choueiri(Co-Founder; Director, Lank Center for GU Oncology, Dana-Farber Cancer Institute)Matthew Freedman(Co-Founder; Professor of Medicine, Dana-Farber Cancer Institute)
Co-investorsIllumina Ventures5AM VenturesOUP (Osage University Partners)Lilly Asia Ventures
BiotechSouth San Francisco, US
Grace Lu(Executive Officer)James Christensen(Executive Officer, Director)Charles Baum(Executive Officer, Director)
BoardMichael Goller(Director)Reid Huber(Director)inPeter Thompson(Director)
Co-investorsRA CapitalEcoR1 CapitalNovo HoldingsOrbiMedThird Rock Ventures
Tessera Therapeutics develops Gene Writing, a genome engineering technology platform designed to make permanent alterations to the human genome for treating diseases.
BiotechDigital HealthMedical Devices
Co-investorsArtis VenturesFlagship PioneeringMarch Capital PartnersOMX VenturesSoftBank Vision FundSolari Capital+4 more
Tessera provides a multi-agent AI platform for enterprise system modernization, automating processes across ERP, CRM, HCM, and finance systems with governed execution.
AI & Machine LearningEnterprise SoftwareSaaS
Kabir Nagrecha(Chief Executive Officer)inMing Chang(Chief Operating Officer)inAnirudh Sriram(Chief Technology Officer)inPrakash Gupta(Chief Revenue Officer)in
Co-investorsAndreessen HorowitzFoundation CapitalMyriad Venture PartnersOUP (Osage University Partners)
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.